Preventing breast cancer in high-risk women, 2008

ONCOLOGY

Volumn 22, Issue 6, 2008, Pages 666-673

  Vogel, Victor G ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER INVASION; CANCER PREVENTION; CANCER RISK; CATARACT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DEPRESSION; DRUG EFFICACY; ENDOMETRIUM CANCER; FEMALE; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MENOPAUSAL SYNDROME; POSTMENOPAUSE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE; THROMBOEMBOLISM; UTERUS CANCER; UTERUS TUMOR; VAGINA DISCHARGE; VASOMOTOR DISORDER; ALGORITHM; BREAST TUMOR; GENETIC PREDISPOSITION; PRACTICE GUIDELINE; REVIEW;

ALGORITHMS; ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PRACTICE GUIDELINES AS TOPIC; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 49149106795     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Vogel VG: Epidemiology of breast cancer, in Bland KI, Copeland EM (eds): The Breast: Comprehensive Management of Benign and Malignant Disease, 3rd ed, vol 1, pp 341-354. Philadelphia, WB Saunders, 2004.
2. Gierach G, Vogel V: Epidemiology of breast cancer, in Singletary SE, Robb GL, Hortobagyi GN (eds): Advanced Therapy of Breast Disease, 2nd ed, pp 58-83. Hamilton, Ontario, BC Decker, 2004.
3. Vogel VG: Epidemiology of breast cancer, in Winchester DJ, Winchester DP, Hudis CA, Norton L (eds): Breast Cancer, 2nd ed, pp 47-60. Hamilton, Ontario, BC Decker, 2006.
4. Hollingsworth AB, Singletary SE, Morrow M, et al: Current comprehensive assessment and management of women at increased risk for breast cancer. Am J Surg 187:349-362, 2004.
5. Vogel V: Atypia in the assessment of breast cancer risk: Implications for management. Diagnostic Cytopath 30:151-157, 2004.
6. Thull D, Vogel VG: Recognition and management of hereditary breast cancer syndromes. Oncologist 9:13-24, 2004.
7. Eliassen AH, Missmer SA, Tworoger SS, et al: Endogenous steroid hormone concentrations and risk of breast cancer: Does the association vary by a woman's predicted breast cancer risk? J Clin Oncol 24:1823-1830, 2006.
8. Vogel VG: Management of the high-risk patient. Surg Clin North Am 83:733-751, 2003.
9. Vogel VG: Reducing the risk of breast cancer with tamoxifen in women at increased risk. J Clin Oncol 19(18s):87s-92s, 2001.
10. Vogel VG: Chemoprevention strategies 2006. Curr Treat Options Oncol 8:74-88, 2007.
11. Gail MH, Brinton LA, Byar DP, et al: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879-1886, 1989.
12. Costantino JP, Gail MH, Pee D, et al: Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91:1541-1548, 1999.
13. Rockhill B, Spiegelman D, Byrne C, et al: Validation of the Gail et al model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93:358-366, 2001.
14. Chlebowski RT, Anderson GL, Lane DS, et al: Predicting risk of breast cancer in post-menopausal women by hormone receptor status. J Natl Cancer Inst 99:1695-1705, 2007.
15. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998.
16. Day R, Ganz PA, Costantino JP, et al: Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 17:2659-2669, 1999.
17. Day R, Ganz PA, Costantino JP: Tamoxifen and depression: More evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) randomized study. J Natl Cancer Inst 93:1615-1623, 2001.
18. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 97:1652-1662, 2005.
19. IBIS Investigators: First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial. Lancet 360:817-824, 2002.
20. Tyrer J, Duffy SW, Cuzick J: A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23:1111-1130, 2004.
21. Cuzick J, Forbes JF, Sestak I, et al: Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99:272-282, 2007.
22. Cuzick J, Powles T, Veronesi U, et al: Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296-300, 2003.
23. Veronesi U, Maisonneuve P, Sacchini V, et al: Tamoxifen for breast cancer among hysterectomised women. Lancet 359:1122-1124, 2002.
24. Veronesi U, Maisonneuve P, Rotmensz N, et al: Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 95:160-165, 2003.
25. Vogel VG: Raloxifene: A second-generation selective estrogen receptor modulator for reducing the risk of invasive breast cancer in postmenopausal women. Women's Health 3:139-153, 2007.
26. Cummings SR, Eckert S, Krueger KA, et al: The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189-2197, 1999.
27. Martino S, Cauley JA, Barrett-Connor E, et al: Continuing Outcomes Relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96:1751-1761, 2004.
28. Barrett-Connor E, Mosca L, Collins P, et al: Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125-137, 2006.
29. Vogel VG, Costantino, JP, Wickerham, DL, et al: Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 295:2727-2741, 2006.
30. Land SR, Wickerham DL, Costantino JP, et al: Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2742-2751, 2006.
31. Freedman AN, Graubard BI, Rao SR, et al: Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 95:526-532, 2003.
32. Gail MH, Costantino JP, Bryant J, et al: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91:1829-1846, 1999.
33. Schrag D, Kuntz KM, Garber JE, et al: Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 283:617-624, 2000.
34. Grann VR, Sundararajan V, Jacobson JS, et al: Decision analysis of tamoxifen for the prevention of invasive breast cancer. Cancer J 6:169-178, 2000.
35. Grann VR, Jacobson JS, Thomason D, et al: Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/ 2 mutations: An updated decision analysis. J Clin Oncol 20:2520-2529, 2002.
36. Hershman D, Sundararajan V, Jacobson JS, et al: Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: A cost-effectiveness analysis. J Clin Oncol 20:9-16, 2002.
37. Ingle JN: Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings. Clin Cancer Res 11:900s-905s, 2005.
38. Goss PE, Strasser-Weippl K: Aromatase inhibitors for chemoprevention. Best Pract Res Clin Endocrinol Metab 18:113-130, 2004.
39. Kinsinger LS, Harris R, Woolf SH, et al: Chemoprevention of breast cancer: A summary of the evidence for the U.S. Preventative Services Task Force. Ann Intern Med 137:59-69, 2002.
40. Chlebowski RT, Col N, Winer EP, et al: American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. In press.